An overview of recent advances in pathogenesis and diagnosis of preeclampsia

Iranian Journal of Kidney Diseases

Volumn 6, Issue 5, 2012, Pages 334-338

  Savaj, Shokoufeh ^a   Vaziri, Nosratolah D ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diagnosis; Pathogenesis; Preeclampsia

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANGIOGENIC FACTOR; ANGIOTENSIN 1 RECEPTOR; ASCORBIC ACID; CALCIUM; ENDOGLIN; FISH OIL; IMMUNOLOGICAL MEDIATOR; MEDIATOR COMPLEX; PLACENTAL GROWTH FACTOR; SOLUBLE ENDOGLIN; SOLUBLE VASCULAR ENDOTHELIAL GROWTH FACTOR; SOLUBLE VASCULOTROPIN RECEPTOR 1; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

BLOOD FLOWMETRY; CALCIUM INTAKE; DRUG EFFICACY; EARLY DIAGNOSIS; HUMAN; IMMUNE DYSREGULATION; INCIDENCE; LOW DRUG DOSE; MOLECULAR PATHOLOGY; OXYGEN SUPPLY DYSREGULATION; PATHOGENESIS; PREECLAMPSIA; REVIEW; RISK FACTOR; RISK REDUCTION; SCREENING TEST; UTERINE ARTERY VELOCIMETRY; VITAMIN SUPPLEMENTATION;

ANGIOGENIC PROTEINS; ANTIBODIES; BIOLOGICAL MARKERS; FEMALE; HUMANS; INCIDENCE; OXYGEN; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PROGNOSIS; RISK FACTORS;

EID: 84866410147     PISSN: 17358582     EISSN: 17358604     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Hernandez-Diaz S, Toh S, Cnattingius S. Risk of pre-eclampsia in first and subsequent pregnancies: prospective cohort study. BMJ. 2009;338:b2255.
2. Wikstrom AK, Larsson A, Eriksson UJ, Nash P, Norden-Lindeberg S, Olovsson M. Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and lateonset preeclampsia. Obstet Gynecol. 2007;109:1368-74.
3. Stepan H, Unversucht A, Wessel N, Faber R. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension. 2007;49:818-24.
4. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet. 2008;371:75-84.
5. Kullima AA, Kawuwa MB, Audu BM, Usman H, Geidam AD. A 5-year review of maternal mortality associated with eclampsia in a tertiary institution in northern Nigeria. Ann Afr Med. 2009;8:81-4.
6. Gupta SD, Khanna A, Gupta R, Sharma NK, Sharma ND. Maternal mortality ratio and predictors of maternal deaths in selected desert districts in rajasthan a community-based survey and case control study. Womens Health Issues. 2010;20:80-5.
7. Maharlouei N, Zakeri Z, Mazloomi E, Lankarani KB. Maternal mortality rate in Fars Province: trends and associated factors in a community-based survey. Arch Iran Med. 2012;15:14-7.
8. Duckitt K, Harrington D. Risk factors for preeclampsia at antenatal booking: systematic review of controlled studies. BMJ. 2005;330:565.
9. Esplin MS, Fausett MB, Fraser A, et al. Paternal and maternal components of the predisposition to preeclampsia. N Engl J Med. 2001;344:867-72.
10. Robillard PY, Hulsey TC, Alexander GR, Keenan A, de Caunes F, Papiernik E. Paternity patterns and risk of preeclampsia in the last pregnancy in multiparae. J Reprod Immunol. 1993;24:1-12.
11. Salha O, Sharma V, Dada T, et al. The influence of donated gametes on the incidence of hypertensive disorders of pregnancy. Hum Reprod. 1999;14:2268-73.
12. Zhou Y, Damsky CH, Chiu K, Roberts JM, Fisher SJ. Preeclampsia is associated with abnormal expression of adhesion molecules by invasive cytotrophoblasts. J Clin Invest. 1993;91:950-60.
13. Zhou Y, Damsky CH, Fisher SJ. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? J Clin Invest. 1997;99:2152-64.
14. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002;20:4368-80.
15. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4-25.
16. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12:642-9.
17. Stepan H, Geipel A, Schwarz F, Kramer T, Wessel N, Faber R. Circulatory soluble endoglin and its predictive value for preeclampsia in second-trimester pregnancies with abnormal uterine perfusion. Am J Obstet Gynecol. 2008;198:175 e1-6.
18. Trogstad L, Magnus P, Stoltenberg C. Pre-eclampsia: Risk factors and causal models. Best Pract Res Clin Obstet Gynaecol.25:329-42.
19. Basso O, Christensen K, Olsen J. Higher risk of preeclampsia after change of partner. An effect of longer interpregnancy intervals? Epidemiology. 2001;12:624-9.
20. Wenzel K, Rajakumar A, Haase H, et al. Angiotensin II type 1 receptor antibodies and increased angiotensin II sensitivity in pregnant rats. Hypertension.58:77-84.
21. Dekker GA. Risk factors for preeclampsia. Clin Obstet Gynecol. 1999;42:422-35.
22. Granger JP, LaMarca BB, Cockrell K, et al. Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular-renal dysfunction in response to placental ischemia. Methods Mol Med. 2006;122:383-92.
23. Gadonski G, LaMarca BB, Sullivan E, Bennett W, Chandler D, Granger JP. Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of interleukin 6. Hypertension. 2006;48:711-6.
24. Burton GJ, Jauniaux E. Oxidative stress. Best Pract Res Clin Obstet Gynaecol.25:287-99.
25. Verlohren S, Herraiz I, Lapaire O, et al. The sFlt-1/ PlGF ratio in different types of hypertensive pregnancy disorders and its prognostic potential in preeclamptic patients. Am J Obstet Gynecol.206:58 e1-8.
26. Benton SJ, Hu Y, Xie F, et al. Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays. Am J Obstet Gynecol.205:469 e1-8.
27. Cnossen JS, Vollebregt KC, de Vrieze N, et al. Accuracy of mean arterial pressure and blood pressure measurements in predicting pre-eclampsia: systematic review and meta-analysis. BMJ. 2008;336:1117-20.
28. Yu CK, Smith GC, Papageorghiou AT, Cacho AM, Nicolaides KH. An integrated model for the prediction of preeclampsia using maternal factors and uterine artery Doppler velocimetry in unselected low-risk women. Am J Obstet Gynecol. 2005;193:429-36.
29. Espinoza J, Romero R, Nien JK, et al. Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. Am J Obstet Gynecol. 2007;196:326 e1-13.
30. Roberge S, Giguere Y, Villa P, et al. Early Administration of Low-Dose Aspirin for the Prevention of Severe and Mild Preeclampsia: A Systematic Review and Meta-Analysis. 2012;29:551-6.
31. Makrides M, Duley L, Olsen SF. Marine oil, and other prostaglandin precursor, supplementation for pregnancy uncomplicated by pre-eclampsia or intrauterine growth restriction. Cochrane Database Syst Rev. 2006CD003402.
32. Basaran A, Basaran M, Topatan B. Combined vitamin C and E supplementation for the prevention of preeclampsia: a systematic review and meta-analysis. Obstet Gynecol Surv.65:653-67.
33. Hofmeyr GJ, Atallah AN, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev. 2006 CD001059.